Effects of Altitude-like Cognition Training on Neuroplasticity and Cognitive Functions

Depression Clinical Trial

— ALTIBRAIN  

Official title:

Altitude-like Cognition Training to Target Brain Erythropoietin as a Novel Mechanism of Long-lasting Neuroplasticity and Cognitive Functions

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06121206
• Other study ID #: H-22028111
• Secondary ID: P-2022-354
• Status: Recruiting
• Phase: N/A
• Start date: January 1, 2023
• Est. completion date: June 2025

Study information

• Verified date: November 2023
• Source: Mental Health Services in the Capital Region, Denmark
• Contact: Kamilla W Miskowiak, DMSc, DPhil
• Phone: +4522771617
• Email: kamilla.woznica.miskowiak[@]regionh.dk
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this clinical trial is to investigate the effects of a three-week altitude-like cognition training intervention in healthy individuals (substudy 1) and symptomatically stable patients with mood disorders (depression or bipolar disorder; substudy 2). This multi-modal intervention consists of an adaptive cognitive training programme that participants complete while they're inside an altitude-training room with 12% O2, corresponding to 4400 meters altitude.

Across substudy 1 and 2, the investigators hypothesize that altitude-like cognition training has a beneficial effect on cognition after three-weeks treatment completion measured with a global cognition composite score (primary outcome measure). Further, the investigators hypothesize that hypoxia and cognition training will yield improved executive functioning after treatment completion and changes in brain activity during working memory in the dorsal prefrontal cortex 4 weeks after treatment completion (secondary outcome measures). In the patient study, the investigators further hypothesize that the intervention will have beneficial effects on daily-life cognition measured in virtual reality (VR) 4 weeks after treatment completion (secondary outcome measure in substudy 2). For exploratory purposes, the study will examine effects on additional measures of cognition, functioning and self-ratings scales (tertiary outcomes).

The investigators will compare the combination of altitude-like hypoxia (12%) and cognitive training with (1) hypoxia with no training, (2) cognitive training under normal oxygen levels (normoxia; 20%), and (3) normoxia with no training in healthy individuals (substudy 1). For patients with mood disorders (substudy 2) the effects of altitude-like hypoxia (12%) and cognitive training are compared to treatment as usual (TAU).

Description:

ALTIBRAIN aims to test a novel model, linking altitude-like oxygen manipulations, endogenous erythropoietin (EPO) in the brain, neuroplasticity and cognition. Specifically, ALTIBRAIN will determine whether upregulation of endogenous brain EPO by altitude-like hypoxia cognition training is a fundamental mechanism of enduring neuroplasticity and long-lasting cognitive improvement in humans. This will be investigated in healthy individuals (substudy 1) and symptomatically stable patients with mood disorders (depression or bipolar disorder; substudy 2).

Substudy 1 involves four intervention groups: (1) altitude-like hypoxia (12%) combined with cognitive training, (2) hypoxia with no training, (3) cognitive training under normoxia (20%), and (4) normoxia with no training. Participants are randomised in blocks of four and undergo interventions in these groups for practical reasons. During the 3-weeks treatment, participants breathe 12% ambient oxygen (≈4400 meters altitude) or normal sea-level oxygen (20%) in a treatment room, 3.5 hours daily, six days per week. On iPads, they perform cognitive training or matched control games without cognitive benefits. Cognitive training is interleaved by short breaks, during which the participants can relax or walk on a treadmill inside the room. Participants undergo cognition assessments in weeks 1 (baseline), 4 and 8 and functional and structural MRI in weeks 1 and 8, when red blood cells are comparable between groups. A subgroup will also undergo PET scanning in week 4.

In substudy 2, patients are randomized to either (1) altitude-like hypoxia (12%) combined with cognitive training, 3.5 hours daily, five-six days per week for three weeks or (2) treatment as usual (TAU). After completed testing, patients in the TAU group undergo the 3-week active intervention, followed by an additional session of neurocognitive testing in the week after treatment completion. All remaining study procedures are identical to substudy 1.

The power calculation was based on the primary hypothesis that altitude-like hypoxia combined with cognitive training produces robust sustained cognitive improvement compared with normoxia and no training. To accommodate for up to a 15% drop-out, we will include 30 participants per group; i.e., 120 healthy individuals and 60 patients to obtain complete data for minimum 26 participants per group, i.e., 104 healthy individuals and 52 patients.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 180
• Est. completion date: June 2025
• Est. primary completion date: June 2025
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria (substudy 1):

• 18-50 years

• No psychiatric history

• Fluency in Danish

Inclusion Criteria (substudy 2):

• 18-65 years

• International Classification of Diseases (ICD)-10 diagnosis of Bipolar Disorder or depression confirmed with the Schedules for Clinical Assessment in Neuropsychiatry (SCAN)

• Fluency in Danish

• Partial or full remission (defined as a score of =14 on the Hamilton Depression Rating Scale 17-items (HDRS-17) and the Young Mania Rating Scale (YMRS)

• Objectively-verified cognitive impairment according to Screen for Cognitive Impairment in Psychiatry (SCIP) and/or self-reported cognitive impairment measured with Cognitive Complaints in Bipolar disorder Rating Assessment (COBRA). For SCIP, their performance must be =0.5 standard deviations (SD) below their demographically adjusted expected total SCIP score or on minimum 2 SCIP subtest scores. For COBRA, patients must report substantial cognitive impairment defined as a score =14.

Common Exclusion Criteria:

• Schizophrenia or schizoaffective disorder

• Neurological disorder

• Alcohol or substance abuse

• History of serious head trauma

• Previous altitude sickness

• Heart disease

• Diabetes

• Renal failure

• Untreated/insufficiently treated hypertension

• Thromboses or thromboembolic events

• First-degree family with thromboembolic events before age 60

• Pregnancy

• Breastfeeding

• Smoking or use other nicotine products regularly

• BMI>30

• Electroconvulsive therapy (ECT) 3 months prior to participation

• Dyslexia

• Claustrophobia (MRI scans)

• Pacemaker and/or other MRI incompatible metal implants (MRI scans)

• Participation in experiments with radioactivity (>10 mSv) within the last year (PET scans)

• Significant occupational exposure to radioactivity (PET scans)

• Medication incompatible with study aims (e.g., SV2A binding agents; PET scans)

Related Conditions & MeSH terms

• Bipolar Disorder
• Cognitive Dysfunction
• Cognitive Impairment
• Depression

Intervention

Other:
• Altitude-like hypoxia (12% O2)
Fresh air with 12% O2, is blown into a sealed 20 m³ room by a 4kW air compressor with a safety-approved system developed by HöhenBalance, Austria. After participants enter the room, the O2 levels will be reduced from 16% to 12% (˜ 4,400 meters altitude) in a 30 minutes lead-in phase. The target O2 level of 12% will be maintained over three hours
• Normoxia (20% O2)
Fresh air with 20% O2, is blown into a sealed 20 m³ room by a 4kW air compressor with a safety-approved system developed by HöhenBalance, Austria. The target O2 level of 20% will be maintained over 3.5 hours

Behavioral:
• Cognitive training
The web-based cognitive training (Happy Neuron Pro) is grounded on principles of neuroplasticity-based learning by being intensive, neuroadaptive, engaging and rewarding. The active training involves parametric task adjustment by decreasing stimuli presentation time, increasing working memory load, decreasing time to respond, and increasing the number of non-target items (distractors).
• Sham training
Participants in the no training control condition receive computer games similar to Happy Neuron Pro but with low cognitive demand that produce no cognitive benefits. Specifically, this sham procedure involves the exact same stimuli as the active condition but with changes from trial to trial only in the appearance of the tasks.

Locations

Country	Name	City	State
Denmark	Neurocognition and Emotion in Affective Disorders (NEAD) Centre, University of Copenhagen and Psychiatric Centre Copenhagen, Frederiksberg hospital	Copenhagen	Capital Region Of Copenhagen

Sponsors (4)

Lead Sponsor	Collaborator
Mental Health Services in the Capital Region, Denmark	European Research Council, Rigshospitalet, Denmark, University of Copenhagen

Country where clinical trial is conducted

Denmark, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Rey Auditory Verbal Learning Test	Neuropsychological test assessing verbal memory. Outcomes include total recall (score range 0-75), immediate recall (score range 0-15), delayed recall (score range 0-15) and recognition (score range 0-15). Higher scores mean a better outcome	Baseline, week 4 (end of treatment), and week 8 (+end of treatment follow-up for patients in treatment as usual group)
Other	Trail Making Test Part A	Neuropsychological test assessing attention and processing speed. Scored as time to complete. A higher time means a worse outcome.	Baseline, week 4 (end of treatment), and week 8 (+end of treatment follow-up for patients in treatment as usual group)
Other	Trail Making Test Part B	Neuropsychological test assessing executive functions. Scored as time to complete. A higher time means a worse outcome.	Baseline, week 4 (end of treatment), and week 8 (+end of treatment follow-up for patients in treatment as usual group)
Other	Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Coding	Neuropsychological test assessing attention. Score range 0-89. Higher scores mean a better outcome.	Baseline, week 4 (end of treatment), and week 8 (+end of treatment follow-up for patients in treatment as usual group)
Other	Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Digit Span	Neuropsychological test assessing executive functions. Score range 0-16. Higher scores mean a better outcome.	Baseline, week 4 (end of treatment), and week 8 (+end of treatment follow-up for patients in treatment as usual group)
Other	Wechsler Adult Intelligence Scale (WAIS)-III Letter-Number Sequencing	Neuropsychological test assessing executive functions. Score range 0-21. Higher scores mean a better outcome.	Baseline, week 4 (end of treatment), and week 8 (+end of treatment follow-up for patients in treatment as usual group)
Other	Verbal fluency with the letter "D" and 'S"	Neuropsychological test assessing executive functions. No score range. Higher scores mean a better outcome.	Baseline, week 4 (end of treatment), and week 8 (+end of treatment follow-up for patients in treatment as usual group)
Other	Rapid Visual Information Processing (RVP) from Cambridge Cognition (CANTAB)	Neuropsychological test assessing sustained attention. Outcomes include signal detection (score range 0-1, higher scores mean a better outcome), probability of hit (score range 0-1, higher scores mean a better outcome), total false alarms (score range 0-546, higher scores mean a worse outcome), and latency to correct (score range 100-1900, higher scores mean a worse outcome).	Baseline, week 4 (end of treatment) and week 8 (+end of treatment follow-up for patients in treatment as usual group)
Other	Spatial Working Memory (SWM) from Cambridge Cognition (CANTAB)	Neuropsychological test assessing visual working memory. Outcomes include errors (score range 0-153, higher scores mean a worse outcome) and strategy (score range 3-26, higher scores mean a worse outcome).	Baseline, week 4 (end of treatment) and week 8 (+end of treatment follow-up for patients in treatment as usual group)
Other	One Touch Stockings of Cambridge (OTS) from Cambridge Cognition (CANTAB)	Neuropsychological test assessing executive functions. Apart from problems solved on first choice (secondary outcome), outcomes include mean choices to correct (score range 1-7, higher scores mean a worse outcome), and latency to correct (no score range, higher scores mean a worse outcome).	Baseline, week 4 (end of treatment) and week 8 (+end of treatment follow-up for patients in treatment as usual group)
Other	Emotion Recognition Task (ERT) from Cambridge Cognition (CANTAB)	Neuropsychological test assessing social cognition. Outcomes include reaction time (no score range, higher scores mean a worse outcome) and hit rate (score range 0-1, higher scores mean a better outcome).	Baseline, week 4 (end of treatment) and week 8 (+end of treatment follow-up for patients in treatment as usual group)
Other	Wisconsin Card Sorting Task (WCST)	Neuropsychological test assessing executive function. No score range. Higher scores mean a worse outcome.	Baseline, week 4 (end of treatment) and week 8 (+end of treatment follow-up for patients in treatment as usual group)
Other	Cognition Assessement in Virtual Reality (CAVIR) test	The CAVIR test is a self-administered 360º immersive VR test in a kitchen, where the participant's abilities to plan and prepare a meal are assessed. The test involves five subtasks probing verbal memory, executive functions, processing speed, working memory and sustained attention. No score range. Higher scores mean a better outcome.	Baseline and week 8 (+end of treatment follow-up for patients in treatment as usual group)
Other	The Assessment of Quality of Life (AQoL)	Questionnaire on quality of life. Score range 33-176. Higher scores mean a worse outcome.	Baseline, week 4 (end of treatment), and week 8 (+end of treatment follow-up for patients in treatment as usual group)
Other	World Health Organization Quality of Life (WHOQoL-BREF)	Questionnaire on quality of life. Score range 26-130. Higher scores mean a better outcome.	Baseline, week 4 (end of treatment), and week 8 (+end of treatment follow-up for patients in treatment as usual group)
Other	Cognitive Complaints in Bipolar Disorder Rating Assessment (COBRA)	Questionnaire on subjective cognitive complaints. Score range 0-48. Higher scores mean a worse outcome.	Baseline, week 4 (end of treatment), and week 8 (+end of treatment follow-up for patients in treatment as usual group)
Other	Work and Social Adjustment Scale (WSAS)	Questionnaire on occupational functioning. Score range 0-40. Higher scores mean a worse outcome.	Baseline, week 4 (end of treatment), and week 8 (+end of treatment follow-up for patients in treatment as usual group)
Other	Sheehan Disability Scale (SDS)	Questionnaire on daily functioning. Score range 0-30. Higher scores mean a worse outcome.	Baseline, week 4 (end of treatment), and week 8 (+end of treatment follow-up for patients in treatment as usual group)
Other	Pittsburgh Sleep Quality Index (PSQI)	Questionnaire on sleep quality. Score range 0-21. Higher scores mean a worse outcome.	Baseline, week 4 (end of treatment), and week 8 (+end of treatment follow-up for patients in treatment as usual group)
Other	ONLY IN PATIENTS (SUBSTUDY 2): Functional Assessment Short Test (FAST)	Clinical interview on daily functioning. Score range 0-72. Higher scores mean a worse outcome.	Baseline and week 8
Primary	Cognitive composite score	A cognitive composite based on an average of Z-transformed scores from the Rey Auditory Verbal Learning Test (RAVLT), Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Coding, verbal fluency with the letter "D", WAIS-III Letter-Number Sequencing, Trail Making Test B (TMT B) and Rapid Visual Information Processing (RVP) speed for correct responses from Cambridge Cognition (CANTAB). No score range. Higher scores mean a better outcome.	Baseline, week 4 (end of treatment. Primary outcome assessement time point), and week 8 (+end of treatment follow-up for patients in treatment as usual group)
Secondary	"Problems solved on first choice" in One Touch Stockings of Cambridge (OTS) from Cambridge Cognition (CANTAB)	Neuropsychological test assessing executive functions. Score range 0-15. Higher scores mean a better outcome.	Baseline, week 4 (end of treatment. Secondary outcome assessement time point), and week 8 (+end of treatment follow-up for patients in treatment as usual group)
Secondary	Dorsal prefrontal cortex activity during spatial N-back	Functional magnetic resonance imaging (fMRI) measure of brain activity during a working memory task.	Baseline, week 8
Secondary	ONLY IN PATIENTS (SUBSTUDY 2): Cognition Assessement in Virtual Reality (CAVIR) test: Composite score	Self-administered 360º immersive virtual reality test in a kitchen, where the participant's abilities to plan and prepare a meal are assessed. The test involves five subtasks probing verbal memory, executive functions, processing speed, working memory and sustained attention, which are summarized in a composite score. No score range. Higher scores mean a better outcome.	Baseline, week 8 (secondary outcome assessment time point) (+end of treatment follow-up for patients in treatment as usual group)